. 2021 Jul 5:zxab270. doi: 10.1093/ajhp/zxab270

Table 1.

Comparison of Monoclonal Antibody Therapies for COVID-19

Characteristic	Bamlanivimab⁵	Casirivimab and Imdevimab⁷	Bamlanivimab and Etesevimab⁶
Manufacturer	Eli Lilly	Regeneron Pharmaceuticals	Eli Lilly
Date of EUA	November 9, 2020	November 21, 2020	February 9, 2021
Dose	700 mg of bamlanivimab in 50, 100, 150, 200, or 250 mL	1,200 mg of casirivimab and 1,200 mg of imdevimab in 250 mL	700 mg of bamlanivimab and 1,400 mg of etesevimab in 50, 100, 150, 200, or 250 mL
Minimum infusion time	50 mL over 16 minutes, 100 mL over 27 minutes, 150 mL over 38 minutes, or 250 mL over 60 minutes	250 mL over 60 minutes	Patients ≥50 kg: 50 mL over 21 minutes, 100 mL over 31 minutes, 150 mL over 41 minutes, or 250 mL over 60 minutes Patients <50 kg: 50 mL over 21 minutes, 100 mL over 31 minutes, 150 mL over 41 minutes, or 250 mL over 70 minutes
Stability	Refrigerator: 24 hours Room temperature: 7 hours If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes before administration.	Refrigerator: 36 hours Room temperature: 4 hours If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 30 minutes before administration.	Refrigerator: 24 hours Room temperature: 7 hours If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes before administration.

Abbreviations: COVID-19, coronavirus disease 2019; EUA, emergency use authorization.